Navigation Links
Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
Date:8/31/2011

SAN FRANCISCO, Aug. 31, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced the publication of clinical data on its lead product JX-594 in the journal Nature. For the first time in humans, an oncolytic virus was shown to reproducibly infect, replicate and express transgene products within cancer tissue after intravenous infusion.  Normal tissues were not significantly affected clinically, underscoring the designed selectivity of JX594 for malignant tissue and safety of the product.

"Our platform technology opens up the possibility of selectively expressing multiple transgene products with complementary mechanisms of action at high concentration in tumors systemically. This is a first in medical history," said David Kirn, M.D., president and chief executive officer of Jennerex. "We believe it will take truly innovative, multi-mechanistic approaches to significantly prolong survival, and to potentially cure patients with metastatic solid tumors. JX-594, with its ability to reach tumors systemically after IV infusion, coupled with its three complementary mechanisms of action, represents a bold new approach to the treatment of metastatic cancers."

Dr. Kirn continued, "We look forward to working with our partners on the clinical development of JX-594 in liver, colorectal and other cancer types. We're particularly excited about the TRAVERSE trial, a global, randomized, controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (liver cancer) having failed sorafenib (Nexavar®) treatment, which we plan to initiate this year."

JX-594 replication and engineered transgene expression within solid tumors was evaluated on a Phase 1 dose-escalation trial of intravenous infusion of JX-594. Twenty-three patients with advanced, treatment-refractory
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ETHICON, INC. today announces,revised labeling for REGRANEX ... factor indicated as an adjunct to the,treatment of ... section of the label has been updated to ... epidemiologic data that is the basis for,it. These ...
... Quintiles,Transnational Corp. today announced the appointment of Christopher ... Scientific Officer. Cabell,succeeds Oren Cohen, M.D., who was ... As Chief Medical and Scientific Officer, Cabell will ... and the protection of,human subjects. In addition, he ...
... CUPERTINO, Calif., June 6 DURECT Corporation,(Nasdaq: DRRX ) announced ... conferences in New York, NY., -- Needham ... Thursday, June 12th at 11:30 a.m. EDT. -- Leerink ... 12:45 p.m. EDT. -- Jefferies, 2nd Annual Healthcare ...
Cached Biology Technology:ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01% 2Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer 2
(Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
(Date:4/15/2014)... Md., is home to hundreds of dedicated scientists, ... of the most cutting-edge Earth science innovation and ... innovation has earned a Goddard scientist the 2014 ... and Geography awards the Vega Medal every three ... in the fields of physical geography, exploration or ...
(Date:4/15/2014)... Diana Lados, associate professor of mechanical engineering ... director of the university,s Integrative Materials Design ... achievement awards from leading engineering societies. , ... International, a global association of more than ... the automotive, aerospace, and commercial vehicle industries, ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Goddard scientist receives Vega Medal from King of Sweden 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... most of the Earth,s total biodiversity and play key roles in ... and on it, going. One of the global processes microbes play ... unbalanced. Humans release more carbon into the atmosphere than can be ... Respond," is a free panel discussion set to take place at ...
... MADISON, WI MAY 5, 2011 In their ... Mississippi River and Gulf of Mexico, people have often ... animal operations, for instance, or farmers who apply too ... according to new modeling research that examined phosphorus loading ...
... Philadelphia, PA, May 6, 2011 According to the ... their food budget in restaurants. As it is widely ... prepared at home, is often higher in calories, saturated fat, ... study in the May/June 2011 issue of the Journal ...
Cached Biology News:Study probes sources of Mississippi River phosphorus 2Study probes sources of Mississippi River phosphorus 3Families are 'lovin' it' 2
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: